Filed by newsfilecorp.com Orgenesis Reports 73% Increase in Revenue for the Second Quarter of Fiscal 2018 CDMO segment achieves operating profit of $1.2 million GERMANTOWN, MD

Orgenesis Reports 73% Increase in Revenue

Quarter of Fiscal 2018

CDMO segment achieves operating profit of $1.2 million

GERMANTOWN, MD July 17, 2018 Orgenesis Inc. (Nasdaq:ORGS),

a manufacturer, service provider and developer of advanced cell therapies, today

reported financial results and provided a business update for the fiscal second

quarter ended May 31, 2018.

Fiscal Q2 2018 financial highlights include:

Revenue increases 73% to $4.0 million as compared to $2.3 million for the

corresponding quarter last year;

Generates gross profit of $1.8 million and achieves gross margin of 45%;

CDMO segment records operating profit of $1.2 million;

Ends quarter with $4.5 million of cash and approximately $26 million of

shareholders equity.

Vered Caplan, CEO of Orgenesis, commented, I am pleased to

report that we not only achieved a 73% increase in sales compared to the same

quarter last year, but we generated a 51% sequential increase compared to the

first quarter of fiscal 2018. We attribute this growth to the continued addition

of new customers and expansion of services among our existing customers,

especially as it relates to manufacturing of CAR T-cell therapies. In addition,

gross profit increased to $1.8 million and we achieved gross margin of 45% for

the second quarter of fiscal 2018. Importantly, our CDMO segment achieved an

operating profit of $1.2 million for the second quarter. At the same time, we

have maintained a solid balance sheet and ended the quarter with over $4 million

of cash, positive working capital and approximately $26 million of shareholders

Given our growth and market demand for our services, we

recently formed a strategic partnership with a leading health care investment

firm, Great Point Partners, LLC, which will both advise and invest up to $25

million into our Masthercell Global subsidiary in order to strengthen and expand

our contract development and manufacturing organization (CDMO) business. This

partnership and investment will allow us to expand our services as well as enter

the U.S. market. At the same time, we announced the acquisitions of our CDMO

partners, Atvio Biotech Ltd. in Israel and Curecell Co. Ltd. in South Korea,

which will further enhance our global footprint within the Middle East and

Revenue for the three months ended May 31, 2018 increased 73%

to $4.0 million, compared to $2.3 million for the three months ended May 31,

2017. Gross profit increased to $1.8 million for the three months ended May 31,

2018, compared $1.2 million for the same period last year. Operating loss was

$2.8 million for the three months ended May 31, 2018, compared to $2.3 million

for the same period last year. The Company achieved an operating profit of $1.2

million within its CDMO segment. Net loss for the three months ended May 31,

2018 was $2.6 million or $0.20 per diluted share, compared to $2.5 million or

$0.26 per diluted share for the three months ended May 31, 2017.

As of May 31, 2018, the Company reported $4.5 million of cash

and approximately $26 million of shareholders equity.

Complete financial results are available in the Company s

Quarterly report on Form 10-Q filed with the Securities and Exchange Commission,

which is available on the Company s website at www.orgenesis.com or at

Orgenesis is a vertically-integrated

biopharmaceutical company with expertise and unique experience in cell therapy

development and manufacturing. Through its Israeli subsidiary, Orgenesis Ltd.,

Orgenesis is developing technology designed to successfully reprogram human

liver cells into glucose-responsive, fully functional, Insulin Producing Cells

(IPCs). Orgenesis believes that converting the diabetic patient's own tissue

into insulin-producing cells has the potential to overcome the significant

issues of donor shortage, cost and exposure to chronic immunosuppressive therapy

associated with islet cell transplantation. Through its Masthercell Global

subsidiary, a global contract development and manufacturing organization (CDMO),

Orgenesis is able to deliver optimized process industrialization capacities to

cell therapy organizations and speed up the arrival of their therapies onto the

market. From technology selection to business modeling, GMP manufacturing,

process development, quality management and assay development, Masthercell s

teams are fully committed to helping their clients fulfill their objective of

providing sustainable and affordable therapies to their patients. Masthercell

operates in a validated and flexible facility located in the strategic center of

Europe within the Walloon healthcare cluster, Biowin. This integrated approach

supports the Company's business philosophy of bringing to market significant

life-improving medical treatments. For more information, visit

Notice Regarding Forward-Looking Statements

press release contains forward-looking statements which are made pursuant to

the safe harbor provisions of Section 27A of the Securities Act of 1933, as

amended and Section 21E of the Securities and Exchange Act of 1934, as

amended t. These forward-looking statements involve substantial

uncertainties and risks and are based upon our current expectations, estimates

and projections and reflect our beliefs and assumptions based upon information

available to us at the date of this release. We caution readers that

forward-looking statements are predictions based on our current expectations

about future events. These forward-looking statements are not guarantees of

future performance and are subject to risks, uncertainties and assumptions that

are difficult to predict. Our actual results, performance or achievements could

differ materially from those expressed or implied by the forward-looking

statements as a result of a number of factors, including, but not limited to,

the success of our reorganized CDMO operations, the success of our partnership

with Great Point, our ability to achieve and maintain overall profitability, the

success of our business model, the sufficiency of working capital to realize our

business plans, the development of our transdifferentiation technology as

therapeutic treatment for diabetes which could, if successful, be a cure for

insulin dependent diabetes; our technology platforms not functioning as

expected; our ability to retain key employees; our ability to satisfy the

rigorous regulatory requirements for new procedures; our competitors developing

better or cheaper alternatives to our products and the risks and uncertainties

discussed under the heading "RISK FACTORS" in Item 1 of our Annual Report on

Form 10-K for the fiscal year ended November 30, 2017, and in our other filings

with the Securities and Exchange Commission. We undertake no obligation to

revise or update any forward-looking statement for any reason.